| For: | Li QY, Lv Y, An ZY, Dai NN, Hong X, Zhang Y, Liang LJ. Ethical review of off-label drugs during the COVID-19 pandemic. World J Clin Cases 2022; 10(17): 5541-5550 [PMID: 35979109 DOI: 10.12998/wjcc.v10.i17.5541] |
|---|---|
| URL: | https://www.wjgnet.com/2307-8960/full/v10/i17/5541.htm |
| Number | Citing Articles |
| 1 |
Andréa Dâmaso Bertoldi, Fernando Silva Guimarães, Alexandra Crispim Boing, Marysabel Pinto Telis Silveira, Pedro Curi Hallal, Mariângela Freitas da Silveira. Pediatric Use of Off‐Label Medicines and Nonevidence‐Based Supplements for COVID‐19: Findings From the 2015 Pelotas Birth Cohort Study (Brazil). Pharmacoepidemiology and Drug Safety 2026; 35(9) doi: 10.1002/pds.70460
|
| 2 |
Ivo Heyerdahl-Viau, Carlos Olaf Sánchez-German, Armando Gómez-Sánchez, Francisco Javier Prado-Galbarro, Mireya García-Casas, Alfonso Mata-Bermudez, Juan Manuel Martínez-Núñez. Drug-related problems, adverse drug reactions, and drug–drug interactions as a result of a pandemic that took us by surprise: COVID-19 in Mexico. RPS Pharmacy and Pharmacology Reports 2025; 4(4) doi: 10.1093/rpsppr/rqaf009
|
| 3 |
Daniel Furtner, Gabor Hutas, Bryan Jie Wen Tan, Roland Meier. Journey from an Enabler to a Strategic Leader: Integration of the Medical Affairs Function in ESG Initiatives and Values. Pharmaceutical Medicine 2023; 37(6) doi: 10.1007/s40290-023-00485-9
|
| 4 |
S. V. Russkikh, E. A. Tarasenko, L. I. Moskvicheva, S. A. Orlov, A. A. Tryakin, A. V. Vorobeva, O. A. Beneslavskaya, V. I. Makarova, E. A. Putilina, S. A. Utkin. “Off-label” drugs: legal problems and socio-economic aspects of application practice. Pharmacy & Pharmacology 2023; 11(2) doi: 10.19163/2307-9266-2023-11-2-149-160
|